NextCell’s CSO Appointed to the Board of ATMP Sweden

March 28, 2025

NextCell Pharma AB ("NextCell") proudly announces that the company’s Chief Scientific Officer (CSO), Dr. Lindsay Davies, has been appointed to the board of ATMP Sweden. This further reinforces both her role and NextCell’s position as a key player in the development of advanced therapies, both nationally and internationally.

ATMP Sweden is a key organization for the development and implementation of Advanced Therapy Medicinal Products (ATMPs) in Sweden. By bringing together academia, industry, and healthcare, the organization works to strengthen Sweden’s position as a leader in cell and gene therapies. ATMP Sweden serves as a platform for collaboration, knowledge sharing, and strategic development and plays a crucial role in realizing the potential of advanced therapies within the Swedish healthcare system.

Dr. Lindsay Davies is already a well-established voice in the international cell and gene therapy field. She was recently nominated as Vice President Elect for Europe within the International Society for Cell and Gene Therapy (ISCT), highlighting her influence and leadership on a global scale. As an active member of ISCT’s global industry committee, she has championed key issues related to quality and safety in the development of cell and gene therapies (CGT) and has published scientific articles in the society’s journal Cytotherapy.

“Representing NextCell on the board of ATMP Sweden is an honour and a valuable opportunity to contribute to the strategic development of advanced therapies in Sweden. I look forward to working alongside other leading stakeholders in the field to collectively strengthen Sweden’s position in this rapidly growing industry,” says Dr. Lindsay Davies.

NextCell Pharma is already an active player in the ATMP space through the development of ProTrans, a cell therapy candidate currently undergoing Phase II trials for the treatment of type 1 diabetes. With Lindsay Davies now on the board of ATMP Sweden, the company gains further opportunities to contribute to the national strategy for advanced therapies.

For more information about NextCell Pharma, please contact
Mathias Svahn, CEO
Patrik Fagerholm, CFO
Tel: +46 8 735 55 95
E-mail: info@nextcellpharma.com
Website:www.nextcellpharma.com

Linkedin: https://www.linkedin.com/NextCell-Pharma
Twitter: https://twitter.com/NextCellPharma

For more information about Cellaviva, please contact
Sofie Falk Jansson, CEO Cellaviva AB
Tel: +46 8 735 20 10
E-mail: info@cellaviva.se
Website:www.cellaviva.se

Facebook: https://www.facebook.com/cellavivasverige
Instagram: https://www,instagram.com/cellaviva

Certified Adviser
The company's shares are listed on the Nasdaq First North Growth Market.
RedEye AB is assigned as Certified Adviser.

About NextCell Pharma AB
NextCell is a cell therapy company in Phase II trials with the drug candidate ProTrans for the treatment of type 1 diabetes. The focus is to obtain market approval of ProTrans via a phase III trial. In addition to type 1 diabetes. NextCell owns Cellaviva AB, Scandinavia’s largest private stem cell bank licensed by the Swedish Health Authority (IVO) to preserve and store stem cells from umbilical cord blood and umbilical cord tissue for family use. NextCell also owns QVance which will offer quality control analytics for advanced therapy developers. Furthermore, NextCell owns 8.5% in FamicordTX, a CAR-T start-up in oncology.

Download attachment Read full press release on Cision (external link)

2018-04-27

NextCell enters into Memorandum of Agreement with China General Consulting & Investment Co., Ltd.

NextCell Pharma AB ("NextCell") hereby announces that the company has entered a Memorandum of Agreement with China General Consulting & Investment Co., Ltd. (”CGCI”). The purpose of the agreement is to create a base for future co-operation. The agreement includes that the parties should prioritize working together when it comes to stem cell development and China, but is otherwise without claims or obligations and does not affect NextCell financially. NextCell has developed a patented applied for selection algorithm to ensure the selection and production of potent mesenchymal stem cells in

Read more Read more

2018-03-27

The Data and Safety Monitoring Board approves the usage of medium-dose ProTrans in the ongoing clinical trial.

Stem cell company NextCell Pharma AB ("NXTCL") announces today that the Data and Safety Monitoring Board for the clinical trial using ProTrans has given its approval for the principal investigator professor Per-Ola Carlsson and NextCell to proceed and treat 3 patients in the medium-dose cohort. The Data and Safety Monitoring Boards consists of; Ulf Smith MD, PhD, Professor and Director, Lundberg Laboratory for Diabetes Research, Sahlgrenska Academy and Sahlgrenska University Hospital, Gothenburg; Anders Fasth MD, PhD, Professor of Pediatric Immunology, Sahlgrenska Academy and Chief Physician

Read more Read more

2018-03-14

An update on NextCell Pharma and Nordic Tech House

NextCell Pharma’s (NXTCL) Board decided on 2018-03-13 to utilize its authorization to implement a targeted issue to Nordic Tech House. NextCell Pharma has identified Nordic Tech House as a strategic partner, which justifies deviation from shareholders’ preferential rights. NextCell Pharma buys services from Nordic Tech House to increase exposure of NextCell Pharma and Cellaviva, both to inform about its development of stem cell therapies and stem cell saving and to optimize the digital messaging for the next 2 years. For its Nordic Tech House is paid with shares in NextCell Pharma AB through

Read more Read more

2018-03-14

Nordic Tech House to invest in stem cell company NextCell Pharma

NextCell Pharma (NXTCL), traded at AktieTorget, announces that a collaboration with Nordic Tech House has been agreed upon where Nordic Tech House will invest in NXTCL and develop the digital presence of NXTCL and Cellaviva. The two-year agreement means that Nordic Tech House will be responsible for the total digital presence of NXTCL, with a specific focus on the family stem cell saving service that is offered to expectant parents through the Cellaviva trademark. Isabella Löwengrip, one of the co-owners of Nordic Tech House, will as influencer, mother, entrepreneur and investor increase the

Read more Read more

2018-03-06

NextCell CEO invited speaker at the Swedish National ATMP Conference

NextCell Pharma AB ("NXTCL") announces that its CEO, Mathias Svahn PhD has been invited to speak at the 1st Swedish National Advanced Therapy Medicinal Product Conference held in Lund on March 15th. The topic of the lecture will be ‘Mesenchymal Stem Cells in Clinical Trials for Treatment of Autoimmune Diseases’. More specifically it describes, how NXTCL leads the way with the development of its drug candidate, ProTrans, using pooled mesenchymal stem cells form the umbilical cord. NXTCL is currently conducting a phase I/II trial using its drug candidate ProTrans for the treatment of adult

Read more Read more

2018-02-22

Three patients now treated with NextCells ProTrans stem cells

NextCell Pharma AB ("NXTCL") announces that three type 1 diabetes patients have been treated with ProTrans in the ongoing clinical phase I/II trial. Thus, all patients in the low-dose-cohort have now undergone treatment. The trial performed with NXCTCL's patent-pending ProTrans, is divided into two parts, the first part being a doseescalation phase with 3 + 3 + 3 patients being treated with either a; low, medium or high dose of ProTrans. Now that all patients in the low-dose-cohort have been treated and after the 1-month follow-up is completed we can start inclusion of patients in the

Read more Read more

2018-02-16

NextCell Pharma files patent application

NextCell Pharma AB ("NextCell") announces that the company has filed a patent application to the Swedish Patent and Registration Office. The patent application relates to the Company’s proprietary selection algorithm and formulation of the stem cell drug candidate ProTrans. The selection algorithm is based on multiple functional assays used to identify and select cells and donors with specified desired characteristics. ProTrans is a pooled allogeneic stem cell product, consisting of cells from multiple donors. The pooling process supports the production of large batches. The combination

Read more Read more

2018-01-31

NextCell Pharma changes ticker to NXTCL

NextCell Pharma AB ("NextCell") announces that it will change its ticker on Aktietorget to NXTCL. Since its listing on Aktietorget (2017-07-13), NextCell has been traded using the ticker NEXTCL. Management has decided to change the ticker to NXTCL. The new abbreviation might also be used in general market communications and company branding. The new ticker will become effective as per 2018-02-07, the company name and ISIN-code (SE0009723125) will remain the same. This information is the information that NextCell Pharma AB is required to disclose under the EU Market Abuse Regulation.

Read more Read more